These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34420788)

  • 1. ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence.
    Heijmenberg I; Husain A; Sathkumara HD; Muruganandah V; Seifert J; Miranda-Hernandez S; Kashyap RS; Field MA; Krishnamoorthy G; Kupz A
    Vaccine; 2021 Dec; 39(50):7265-7276. PubMed ID: 34420788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
    Bottai D; Frigui W; Clark S; Rayner E; Zelmer A; Andreu N; de Jonge MI; Bancroft GJ; Williams A; Brodin P; Brosch R
    Vaccine; 2015 May; 33(23):2710-8. PubMed ID: 25869896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.
    Khanna M; Rady H; Dai G; Ramsay AJ
    Vaccine; 2021 Mar; 39(12):1780-1787. PubMed ID: 33632562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes.
    Sathkumara HD; Muruganandah V; Cooper MM; Field MA; Alim MA; Brosch R; Ketheesan N; Govan B; Rush CM; Henning L; Kupz A
    Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20848-20859. PubMed ID: 32778586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection.
    Gröschel MI; Sayes F; Shin SJ; Frigui W; Pawlik A; Orgeur M; Canetti R; Honoré N; Simeone R; van der Werf TS; Bitter W; Cho SN; Majlessi L; Brosch R
    Cell Rep; 2017 Mar; 18(11):2752-2765. PubMed ID: 28297677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
    Valencia-Hernandez AM; Zhao G; Miranda-Hernandez S; Segura-Cerda CA; Pedroza-Roldan C; Seifert J; Aceves-Sanchez MJ; Burciaga-Flores M; Gutierrez-Ortega A; Del Pozo-Ramos L; Flores-Valdez MA; Kupz A
    Vaccine; 2024 Oct; 42(24):126291. PubMed ID: 39241355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
    Brodin P; Majlessi L; Marsollier L; de Jonge MI; Bottai D; Demangel C; Hinds J; Neyrolles O; Butcher PD; Leclerc C; Cole ST; Brosch R
    Infect Immun; 2006 Jan; 74(1):88-98. PubMed ID: 16368961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Promising Listeria-Vectored Vaccine Induces Th1-Type Immune Responses and Confers Protection Against Tuberculosis.
    Yin Y; Lian K; Zhao D; Tao C; Chen X; Tan W; Wang X; Xu Z; Hu M; Rao Y; Zhou X; Pan Z; Zhang X; Jiao X
    Front Cell Infect Microbiol; 2017; 7():407. PubMed ID: 29034213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion: encoded PE-PPE proteins predicts vaccine potential.
    Sayes F; Sun L; Di Luca M; Simeone R; Degaiffier N; Fiette L; Esin S; Brosch R; Bottai D; Leclerc C; Majlessi L
    Cell Host Microbe; 2012 Apr; 11(4):352-63. PubMed ID: 22520463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
    Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
    Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-based delivery system enhances immunogenicity of a tuberculosis subunit vaccine candidate consisting of the ESAT-6:CFP-10 complex.
    Farsiani H; Mosavat A; Soleimanpour S; Sadeghian H; Akbari Eydgahi MR; Ghazvini K; Sankian M; Aryan E; Jamehdar SA; Rezaee SA
    Mol Biosyst; 2016 Jun; 12(7):2189-201. PubMed ID: 27138226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
    Dietrich J; Andersen C; Rappuoli R; Doherty TM; Jensen CG; Andersen P
    J Immunol; 2006 Nov; 177(9):6353-60. PubMed ID: 17056566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis.
    Bao L; Chen W; Zhang H; Wang X
    Infect Immun; 2003 Apr; 71(4):1656-61. PubMed ID: 12654778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model.
    Cervantes-Villagrana AR; Hernández-Pando R; Biragyn A; Castañeda-Delgado J; Bodogai M; Martínez-Fierro M; Sada E; Trujillo V; Enciso-Moreno A; Rivas-Santiago B
    Vaccine; 2013 Jan; 31(4):676-84. PubMed ID: 23196205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
    Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
    J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous BCG driven antigen recognition in a murine tuberculosis model.
    Singh S; Bolz M; Cornelius A; Desvignes L
    Comp Immunol Microbiol Infect Dis; 2022 Aug; 87():101838. PubMed ID: 35700556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice.
    Kirk NM; Huang Q; Vrba S; Rahman M; Block AM; Murphy H; White DW; Namugenyi SB; Ly H; Tischler AD; Liang Y
    Front Immunol; 2023; 14():1127515. PubMed ID: 36845108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells.
    Romagnoli A; Etna MP; Giacomini E; Pardini M; Remoli ME; Corazzari M; Falasca L; Goletti D; Gafa V; Simeone R; Delogu G; Piacentini M; Brosch R; Fimia GM; Coccia EM
    Autophagy; 2012 Sep; 8(9):1357-70. PubMed ID: 22885411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis.
    Tiwari S; Dutt TS; Chen B; Chen M; Kim J; Dai AZ; Lukose R; Shanley C; Fox A; Karger BR; Porcelli SA; Chan J; Podell BK; Obregon-Henao A; Orme IM; Jacobs WR; Henao-Tamayo M
    Vaccine; 2020 Oct; 38(45):7156-7165. PubMed ID: 32978002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.